# CCRM

> CCRM is a VC fund in Toronto backing Biotechnology and Health Care. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Toronto, Canada
- Total investments: 3
- Last investment: Feb 2021
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company-beta/1981928/
- X (Twitter): https://twitter.com/ccrm_ca
- Website: http://www.ccrm.ca/
- Facebook: https://www.facebook.com/commercializinglivingtherapies/

CCRM is a VC fund in Toronto focused on Biotechnology and Health Care. Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today.Many new and potentially life-changing RM-basedtreatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting their population, a world-renowned group of stem cell scientists and bioengineers have come together to form CCRM.CCRM’s mission is to generate sustainable health and economic benefits through global collaboration in cell and gene therapy, and regenerative medicine.

## Contacts

5 contacts available for CCRM. Shizune tracks 4 team members at CCRM. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/centre-for-commercialization-of-regenerative-medicine?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 100% |
| Health Care | 2 | 67% |
| Medical | 1 | 33% |
| Therapeutics | 1 | 33% |
| Developer Platform | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Corporate Round | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Emily Titus | Project Manager & Development Scientist | 0 | — |
| Mitchel Sivilotti | COO | 0 | — |
| Michael May | President & CEO | 0 | — |
| Peter Zandstra | Co-Founder and Chief Scientific Officer | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Notch Therapeutics | Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells. The company's proprietary T-cell production platform enables precision control of Notch signaling, which is required for T-cell development, by combining sophisticated product design with commercial-compatibleprocesses. The ability to control notch signaling eliminates several critical limiting factors in cell therapy development and provides the ability to design and manufacture a consistent and limitless supply of therapeutic T cells.Notch Therapeutics was established in 2018 and is headquartered in Toronto, Canada. | $85M | Series A | Feb 10, 2021 |  |
| Mesentech | Mesentech is a company focused on treating diseases and medical conditions that relate to bone. They are generating a series of products, from different, but complementary approaches that will effectively address currently difficult to treat conditions.Bone can be one of the most difficult organs to access and treat with medicines. It’s hardsurface and low porosity presents challenges in adequately getting drugs to either the bone surface or to its interior. Treatment often requires administering high doses of a drug over extended periods. Not only is achievement of efficacy compromised, but also side- effects may be more prevalent and can limit treatment effectiveness.Mesentech’s lead technology is a proprietary bone targeting system that can effectively deliver small-molecule and biological drugs to the surface or to the interior of bone. Pre-clinical in-vivo models have confirmed the utility of this technology. |  | Corporate Round | Nov 01, 2018 |  |
| KisoJi Biotechnology | KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers. |  | Series A | Oct 12, 2016 |  |

3 of 3 investments shown.

## Co-investors
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 2 deals together
- [Accel-Rx Health Sciences Accelerator](https://shizune.co/investors/profile/accel-rx-health-sciences-accelerator) — VC Fund, 1 deal together
- Allogene Therapeutics — VC Fund, 1 deal together
- Allogene Therapeutics Inc — VC Fund, 1 deal together
- [Amplitude Venture Capital](https://shizune.co/investors/profile/amplitude-venture-capital) — VC Fund, 1 deal together
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does CCRM invest in?

CCRM invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Corporate Round stage. Most of the 3 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact CCRM?

Public channels for CCRM include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at CCRM?

The team at CCRM includes Emily Titus (Project Manager & Development Scientist), Mitchel Sivilotti (COO) and Michael May (President & CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co